-
1
-
-
33646337650
-
Hepatocellular carcinoma and hepatitis B virus
-
Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153-161.
-
(2006)
Semin Liver Dis
, vol.26
, pp. 153-161
-
-
Chan, H.L.1
Sung, J.J.2
-
2
-
-
13444309139
-
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone
-
Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
-
(2005)
Ann Intern Med
, vol.142
, pp. 240-250
-
-
Chan, H.L.1
Leung, N.W.2
Hui, A.Y.3
Wong, V.W.4
Liew, C.T.5
Chim, A.M.6
-
3
-
-
19944428132
-
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
-
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
-
(2005)
Lancet
, vol.365
, pp. 123-129
-
-
Janssen, H.L.1
van Zonneveld, M.2
Senturk, H.3
Zeuzem, S.4
Akarca, U.S.5
Cakaloglu, Y.6
-
4
-
-
21244447705
-
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
-
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
-
(2005)
N Engl J Med
, vol.352
, pp. 2682-2695
-
-
Lau, G.K.1
Piratvisuth, T.2
Luo, K.X.3
Marcellin, P.4
Thongsawat, S.5
Cooksley, G.6
-
5
-
-
80055059164
-
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
-
Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-1599.
-
(2011)
Hepatology
, vol.54
, pp. 1591-1599
-
-
Liaw, Y.F.1
Jia, J.D.2
Chan, H.L.3
Han, K.H.4
Tanwandee, T.5
Chuang, W.L.6
-
6
-
-
1542724805
-
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
-
van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-810.
-
(2004)
Hepatology
, vol.39
, pp. 804-810
-
-
van Zonneveld, M.1
Honkoop, P.2
Hansen, B.E.3
Niesters, H.G.4
Murad, S.D.5
de Man, R.A.6
-
7
-
-
48549107919
-
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
-
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
-
(2008)
Gastroenterology
, vol.135
, pp. 459-467
-
-
Buster, E.H.1
Flink, H.J.2
Cakaloglu, Y.3
Simon, K.4
Trojan, J.5
Tabak, F.6
-
8
-
-
77952725714
-
Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
-
Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.
-
(2010)
Hepatology
, vol.51
, pp. 1945-1953
-
-
Wong, V.W.1
Wong, G.L.2
Yan, K.K.3
Chim, A.M.4
Chan, H.Y.5
Tse, C.H.6
-
9
-
-
70649104668
-
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
-
Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
-
(2009)
Gastroenterology
, vol.137
, pp. 2002-2009
-
-
Buster, E.H.1
Hansen, B.E.2
Lau, G.K.3
Piratvisuth, T.4
Zeuzem, S.5
Steyerberg, E.W.6
-
10
-
-
84863517149
-
Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B
-
Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B. Hepatology 2012;56:67-75.
-
(2012)
Hepatology
, vol.56
, pp. 67-75
-
-
Sonneveld, M.J.1
Rijckborst, V.2
Zeuzem, S.3
Heathcote, E.J.4
Simon, K.5
Senturk, H.6
-
11
-
-
84857636648
-
Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B
-
Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513-520.
-
(2012)
Gastroenterology
, vol.142
, pp. 513-520
-
-
Sonneveld, M.J.1
Wong, V.W.2
Woltman, A.M.3
Wong, G.L.4
Cakaloglu, Y.5
Zeuzem, S.6
-
12
-
-
80054724912
-
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report
-
Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-1131.
-
(2011)
J Hepatol
, vol.55
, pp. 1121-1131
-
-
Chan, H.L.1
Thompson, A.2
Martinot-Peignoux, M.3
Piratvisuth, T.4
Cornberg, M.5
Brunetto, M.R.6
-
13
-
-
84859567945
-
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
-
Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012;61:641-645.
-
(2012)
Gut
, vol.61
, pp. 641-645
-
-
Janssen, H.L.1
Sonneveld, M.J.2
Brunetto, M.R.3
-
14
-
-
77957958049
-
Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline
-
Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline. Hepatology 2010;52:1251-1257.
-
(2010)
Hepatology
, vol.52
, pp. 1251-1257
-
-
Sonneveld, M.J.1
Rijckborst, V.2
Boucher, C.A.3
Hansen, B.E.4
Janssen, H.L.5
-
15
-
-
79952206073
-
Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients
-
Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 2010;53:1054-1055.
-
(2010)
Hepatology
, vol.53
, pp. 1054-1055
-
-
Piratvisuth, T.1
Marcellin, P.2
-
16
-
-
84856203453
-
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-á2b: relation to response and HBV genotype
-
Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-á2b: relation to response and HBV genotype. Antivir Ther 2012;17:9-17.
-
(2012)
Antivir Ther
, vol.17
, pp. 9-17
-
-
Sonneveld, M.J.1
Rijckborst, V.2
Cakaloglu, Y.3
Simon, K.4
Heathcote, E.J.5
Tabak, F.6
-
17
-
-
0344737590
-
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay
-
Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-222.
-
(2004)
J Virol Methods
, vol.115
, pp. 217-222
-
-
Deguchi, M.1
Yamashita, N.2
Kagita, M.3
Asari, S.4
Iwatani, Y.5
Tsuchida, T.6
-
18
-
-
79959247715
-
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B
-
Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51:175-178.
-
(2011)
J Clin Virol
, vol.51
, pp. 175-178
-
-
Sonneveld, M.J.1
Rijckborst, V.2
Boucher, C.A.3
Zwang, L.4
Beersma, M.F.5
Hansen, B.E.6
-
19
-
-
84860320431
-
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
-
Epub ahead of print]
-
Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011 [Epub ahead of print].
-
(2011)
Hepatol Int
-
-
Piratvisuth, T.1
Marcellin, P.2
Popescu, M.3
Kapprell, H.P.4
Rothe, V.5
Lu, Z.M.6
-
20
-
-
77955984417
-
Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B
-
Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010;9:91-98.
-
(2010)
Curr Hepat Rep
, vol.9
, pp. 91-98
-
-
Sonneveld, M.J.1
Janssen, H.L.2
-
21
-
-
38049008387
-
Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B
-
ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, et al. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther 2007;12:1285-1294.
-
(2007)
Antivir Ther
, vol.12
, pp. 1285-1294
-
-
ter Borg, M.J.1
Hansen, B.E.2
Herrmann, E.3
Zeuzem, S.4
Cakaloglu, Y.5
Karayalcin, S.6
-
22
-
-
33748951529
-
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
-
ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006;44:721-727.
-
(2006)
Hepatology
, vol.44
, pp. 721-727
-
-
ter Borg, M.J.1
van Zonneveld, M.2
Zeuzem, S.3
Senturk, H.4
Akarca, U.S.5
Simon, C.6
-
23
-
-
77954412012
-
Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
-
Hansen B, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-1142.
-
(2010)
J Med Virol
, vol.82
, pp. 1135-1142
-
-
Hansen, B.1
Buster, E.H.2
Steyerberg, E.W.3
Lesaffre, E.4
Janssen, H.L.5
-
24
-
-
39549114267
-
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
-
Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.
-
(2008)
Hepatology
, vol.47
, pp. 428-434
-
-
Fried, M.W.1
Piratvisuth, T.2
Lau, G.K.3
Marcellin, P.4
Chow, W.C.5
Cooksley, G.6
-
25
-
-
38349108753
-
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years
-
Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57:84-90.
-
(2008)
Gut
, vol.57
, pp. 84-90
-
-
Fattovich, G.1
Olivari, N.2
Pasino, M.3
D'Onofrio, M.4
Martone, E.5
Donato, F.6
-
26
-
-
84862664371
-
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
-
European Association for the Study of the Liver.
-
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
-
(2012)
J Hepatol
, vol.57
, pp. 167-185
-
-
-
27
-
-
70349240414
-
Chronic hepatitis B: update 2009
-
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
-
(2009)
Hepatology
, vol.50
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
28
-
-
33644858331
-
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
-
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
-
(2006)
Gastroenterology
, vol.130
, pp. 678-686
-
-
Iloeje, U.H.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Chen, C.J.6
-
29
-
-
29944436855
-
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
-
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
-
(2006)
JAMA
, vol.295
, pp. 65-73
-
-
Chen, C.J.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Lu, S.N.6
|